Memorial Sloan Kettering Cancer Center

Where you’re treated first, matters. To make an appointment: 877-871-9362

[Targeted Oncology @TargetedOnc]

At #ESMO26, @DrDarrenFeldman (@MSKCancerCenter) discusses phase 1 data showing ixotatug vedotin drives notable responses in heavily pretreated #GermCellTumors, with manageable ADC safety and potential phase 2 plans.

🎥 WATCH: https://t.co/GqUycNzYWj

#Oncology #CancerTreatment

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

Tomorrow at #ESMO26: MSK gastrointestinal medical oncologist @AndreaCercek will present the first results from the global AZUR1 trial of dostarlimab monotherapy in patients with dMMR/MSI-H locally advanced rectal cancer.

🗓️ Sunday, October 25 | 11:00 a.m. CET

[MSK Department of Medicine @MSK_DeptOfMed]

Today at #ESMO26: Mrinal Gounder will present updated safety and efficacy data from a phase 1/2 trial of zolucatetide in patients with desmoid tumors. @MSKCancerCenter

🗓️ October 24 | 2:55 p.m. CEST

[OncLive.com @OncLive]

🧬 In phase 1 CATALINA-1, ixotatug vedotin achieved a 45.5% response rate in 11 patients with heavily pretreated germ cell tumors. Half of those previously treated with HDCT/ASCT responded.

Read more about the findings presented at @myESMO
#ESMO26 @DrDarrenFeldman @MSKCancerCenter: https://t.co/NgLnGKtauY

[UroToday.com @urotoday]

TORL-1-23: Safety and Efficacy of Ixotatug Vedotin, a Claudin 6-Targeted ADC, as Monotherapy in Germ Cell Tumors. Presented by @DrDarrenFeldman @MSKCancerCenter. #ESMO26 written coverage by @zklaassen_md > https://t.co/HKosJjJFti #TesticularCancer #GermCellTumors #ClinicalTrials @m@myESMO

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

Coming up at #ESMO26: MSK cancer biologist @nikolausschultz will present on AI-augmented integration of real-world data to improve cancer outcome prediction.

🗓️ Saturday, October 24 | 12:20 p.m. CEST

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

Tomorrow at #ESMO26: MSK melanoma medical oncologist Dr. Michael Postow will present a poster on real-world outcomes among patients with resectable stage III melanoma treated with neoadjuvant nivolumab plus relatlimab or nivolumab plus ipilimumab.

🗓️ Saturday, October 24 | 12:00 p.m. CEST

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

Good news for #melanoma cancer patients: New results from a personalized #cancervaccine designed to prevent melanoma from returning after surgery showed positive results, according to research presented at this year’s #ESMO26 meeting in Madrid.

The study found that adding a specially tailored cancer vaccine to standard treatment with immunotherapy successfully reduced the risk of melanoma coming back by 42% compared with standard immunotherapy alone.

“The idea of this treatment is that by specifically boosting a patient’s immune system to recognize their own tumor cells, we can reduce the risk that the cancer comes back,” says Dr. Michael Postow, Chief of the Melanoma Service at MSK. “Even when we can’t see any cancer on a CT or PET scan, we know that often it’s still there — because such a high proportion of patients eventually have a cancer recurrence. That’s why there is tremendous need for this type of treatment.”

Read more about one of the three MSK patients treated in the trial: https://t.co/gEpf7aPXSa

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

A new vaccine continues to show potential as a ready-made treatment for pancreatic cancer, according to a study co-led by MSK researchers.

MSK's @EileenMOReilly presented phase 2 results from AMPLIFY-7P at #ESMO26. The vaccine targets KRAS mutations, which are found in more than 90% of pancreatic cancers.

99% of patients receiving the vaccine developed cancer-fighting immune T cells. Patients with the strongest immune responses had the lowest recurrence rates.

“Having a vaccine that’s ‘off-the-shelf’ would make it easier, faster, and less expensive to treat a larger number of patients,” says Dr. O’Reilly. “This gives hope for people with pancreatic cancer who have been out of effective treatments when their disease returns.” Learn more: https://t.co/gDpJRtWOQd

[MSK Department of Medicine @MSK_DeptOfMed]

Don't miss posters today at #ESMO26: Salomon Tendler will present data showing that DLL3 PET identifies neuroendocrine differentiation and tumor heterogeneity in advanced prostate cancer. @Tendler_S @MSKCancerCenter

📅 October 23 | 3:15 p.m. CEST

[Wungki Park, MD MS @CentralParkWMD]

🧬 One of my FAVORITE pancreatic cancer meetings ever!

The 3rd Botton-Champalimaud International Pancreatic Cancer Conference in beautiful Lisbon 🇵🇹
https://t.co/0A6x9g8AGB

An extraordinary gathering of 💡brilliant minds from around the world, united by one mission: transforming #PancreaticCancer care.

Deep 🧪science, bold ideas and exciting discussions on #KRAS #RAS biology, therapeutic resistance, 🦀tumor evolution 🐒 and the next generation of treatments.

The pace of progress in this field is extraordinary! 🚀

So much learned. So many new ideas. And even more reasons to be optimistic about the future! 💜

#PDAC #TranslationalResearch @MSKCancerCenter @CpcrMsk @MSK_DeptOfMed

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

Coming up at #ESMO26: MSK gastrointestinal medical oncologist @EileenMOReilly will present the AMPLIFY-7P randomized phase 2 study comparing an mKRAS-specific immunotherapy with observation in patients with resected pancreatic ductal adenocarcinoma.

🗓️ Friday, October 23 | 2:32 p.m. CEST

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

Through a recent collaboration, Memorial Sloan Kettering Cancer Center (MSK) and @OpenEvidence are making precision oncology expertise more accessible within clinicians’ everyday workflows.

The collaboration brings OpenEvidence and MSK's OncoKB™ knowledge base together to help deliver trusted, evidence-based guidance when and where it’s needed most.

Watch to learn more ⬇️

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

@OpenEvidence Excited for this important partnership!

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

When the immune system is weakened by cancer treatment — especially by a stem cell or bone marrow transplant (BMT) for blood cancer — common viruses like herpes simplex virus (HSV) can become a serious problem.

For someone who is immunocompromised, an HSV infection can mean dealing with large, painful sores that resist the usual therapies and ultimately lead to more critical medical conditions.

The good news: The @FDA recently approved #pritelivir (Hovilpri) for HSV infection in immunocompromised patients, including those who are undergoing cancer treatment.

The study that resulted in the drug’s approval was co-led by Dr. @GenPapaMD, Clinical Director for Infectious Diseases at MSK, and Dr. June Lee, an infectious disease specialist at MSK, among others.

Learn more: https://t.co/36hhk8lbHy

[Wungki Park, MD MS @CentralParkWMD]

Congratulations 🎉🍾🎊 So so proud to be working with the legends in this team with @AndreaCercek and @ldiaz1971 @MSKCancerCenter

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

New research from MSK uncovers an unknown role for immune cells in fueling triple-negative breast cancer; identifies a new strategy for fighting leptomeningeal metastases; finds trastuzumab deruxtecan shows enhanced benefit for patients with ERBB2 mutations in breast cancer; and more: https://t.co/S0EwaRmTFO

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

🚨: The @FDA has granted accelerated approval to the immunotherapy Jemperli (dostarlimab) for adults with stage 2 or 3 rectal cancer whose tumors have specific genetic characteristics known as mismatch repair-deficient (MMRd) or microsatellite instability-high (MSI-H).

The approach, developed at MSK by gastrointestinal medical oncologists Dr. Andrea Cercek (@AndreaCercek) and Dr. Luis Diaz Jr. (@ldiaz1971), uses immunotherapy alone to harness the body’s own immune system to fight cancer.

This allows some patients to skip standard treatment for rectal cancer, which includes surgery, radiation, and chemotherapy, and can have life-altering consequences for bowel and urinary function, as well as fertility.

Learn more: https://t.co/KBSqnPjL5s

[Waxman Institute @WaxmanCancer]

How does aging influence cancer development & the lung’s ability to regenerate? @TuomasTammela from @MSKCancerCenter, a 2026 Aging & Cancer Awardee, is presenting how aging alters cellular behavior and tumorigenesis #2026agingcancermeeting @TheMarkFdn @AmericanCancer

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

Specialists at MSK know how to modify tests and treatment protocols to navigate the special needs of people who have cancer during pregnancy. Beyond the medical expertise, MSK also offers emotional support for expectant mothers facing a heartbreaking circumstance.

“We are seeing this situation more often because of the rise in certain cancers among younger people,” says MSK psychologist Dr. Amanda Balakirsky. “Being pregnant with cancer can cause a lot of grief and feelings of isolation. We try to normalize the experience as best we can, to help them adjust from what they were expecting in their pregnancy and feeling different from their peers.”

Learn more about how they helped one patient and her now 1.5-year-old son: https://t.co/cmW0gyo36A